JCA-Mauvernay Award
JCA-Mauvernay Award 歴代受賞者一覧
“JCA-Mauvernay Award”規定
2018年12月26日改訂版
- 日本癌学会とDebiopharm社は、2005年1月1日をもって、“JCA-Mauvernay Award”を設ける。この賞は、がんの研究領域において、すぐれた成果をあげられた研究者に対して授与される。
- “JCA-Mauvernay Award”の候補者は日本癌学会の会員であり、日本癌学会評議員の推薦による。
- “JCA-Mauvernay Award”の募集要項は、日本癌学会ホームページ上に掲載するものとし、申請希望者は所定の申請用紙（申請書及び推薦書）を使用の上、指定期日内に申請するものとする。
- 申請書の受付期間は受賞の歴年度の2月1日から3月31日までとする。尚、申請書の記載は英語のみとする。
- 受賞候補者は、申請時に満50歳未満であることとする。
- “JCA-Mauvernay Award”の選考件数は２名を原則とし、うち少なくとも１名はトランスレーショナル研究（TR)領域より選出し、残り１名は研究領域を問わず、次の20年の間にがんの克服につながることが期待される革新的で常識を覆すような研究の発展への貢献に対して選出する。賞の選考は、日本側から6名（日本癌学会賞等選考委員会の6名）と、ヨーロッパ側からの2名（Debiopharm社推薦）から構成される選考委員会がこれにあたり、理事会による承認を経るものとする。
- 受賞者には、賞状、記念品、および副賞（１人あたり12，500スイスフラン）を贈呈し、総会時に授与式を行うものとする。
- 受賞歴のある会員からの再度の申請は認めないものとする。
以上
申請締切り
2021年3月31日(水)当日消印有効
申請書・推薦書様式のダウンロード
申請書・推薦書様式はこちらからダウンロードできます。
ダウンロードした申請書・推薦書様式に入力後、プリントしていただき、推薦書には推薦者サインの上、1部郵送してください。
申請書（Word形式、41KB)お問い合わせ
何か疑問点等がある場合には、下記事務局までお問合せください。
〒160-0016 東京都新宿区信濃町35 信濃町煉瓦館
一般財団法人国際医学情報センター内
一般社団法人 日本癌学会事務局
TEL 03-5361-7156（直通） FAX 03-3358-1633
e-mail：jca.office@imic.or.jp
歴代受賞者一覧
| Year | Categories | winner | affiliation | title of research |
|---|---|---|---|---|
| 2021 | Innovative and/or disruptive research | Shumpei Ishikawa | Professor, Department of Preventive Medicine, Graduate Shool of Medicine, The University of Tokyo | Genomic Characterization of Diffuse-type Gastric Carcinoma Life Cycle |
| Translational Research | Hiromichi Ebi | Division Head, Division of Molecular Therapeutics, Aichi Cancer Center Research Institute | Development of targeted therapies against tumors with aberrant MAPK singnaling | |
| 2020 | Innovative and/or disruptive research | Hideaki Ogiwara | Chief, Division of Cancer Therapeutics, National Cancer Center Research Institute | Development of synthetic lethal therapy for chromatin regulator deficient cancers |
| Translational research | Keisuke Kataoka | Chief, Division of Molecular Oncology, National Cancer Center Research Institute | Genetic dissection of molecular pathogenesis in human cancer | |
| 2019 | Translational research | Ryohei Katayama | Chief, Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research | Identification of the resistance mechanisms to molecular targeted therapies and immune checkpoint inhibitor in lung cancer |
| Innovative and/or disruptive research | Shinichi Yachida | Professor, Department of Cancer Genome Informatic, Graduate School of Medicine, Osaka University | Cancer clonal evolution and involvement ot the microbiota in cancer development | |
| 2018 | Translational Research | Takahiro Maeda | Center for Celluar and Molecular Medicine/ Kyushu University Hospital | Identifying novel targets for leukemia therapy using the CRISPR/Cas9 gene-editing tool |
| Other research area | Tatsushi Igaki | Laboratory of Genetics/ Graduate School of Biostudies Kyoto University | Mechanisms of cell-cell competition and cooperation in tumorigenesis | |
| 2017 | Basic | Yasuhiro Yamada | Laboratory of Stem Cell Oncology, Department of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University | Dissecting cancer epigenetics with reprogramming technology |
| Applied | Hiroyoshi Nishikawa | Division of Cancer Immunology, Research Institute/EPOC, National Cancer Center Department of Immunology, Nagoya University Graduate School of Medicine | Immune suppressive mechanisms as a target of effective cancer immunotherapy | |
| 2016 | Basic | Hidewaki Nakagawa | RIKEN Center for Integrated Medical Sciences, Laboratory for Genome Sequencing Analysis | Cancer Genomics for Molecular Diagnosis and Treatment: Genome Sequencing and Genome-wide Association Study |
| Applied | Hiroyuki Seimiya | Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research | Telomere maintenance system as an anticancer therapeutic target | |
| 2015 | Basic | Yutaka Kondo | Department of Epigenomics, Nagoya City University Graduate School of Medical Sciences | Targeting epigenetics as a new paradigm in cancer treatment |
| Applied | Junko Takita | Department of Pediatrics, Graduate School of Medicine, The University of Tokyo | Identification of molecular therapeutic targets for pediatric cancers | |
| 2014 | Basic | Eiji Hara | Division of Cancer Biology, The Cancer Institute, Japanese Foundation for Cancer Research | Cellular senescence and cancer : a gut microbial connection |
| Applied | Tatsuhiro Shibata | Division of Cancer Genomics, National Cancer Center Research Institute |
Identification and clinical translation of novel diagnostic and therapeutic targets in intractable solid cancers by cancer genome/transcriptome sequencing | |
| 2013 | Basic | Issay Kitabayashi | Division of Hematological Malignancy, National Cancer Center Research Institute | Molecular study of acute myeloid leukemia and its application for therapy |
| Applied | Seiji Yano | Cancer Research Institute Kanazawa University | Circumvention of molecular targeted drug-resistance in lung cancer | |
| 2012 | Basic | Masanobu Oshima | Division of Genetics, Cancer Research Institute Kanazawa University | The role of inflammatory responses in gastric cancer development |
| Applied | Shinji Tanaka | Tokyo Medical and Dental University, Department of Hepato-Biliary-Pancreatic Surgery | Surgical Oncology to Develop Novel Targeted Therapies for Advanced Digestive Cancer | |
| 2011 | Basic | Hirofumi Arakawa | Division of Cancer Biology, National Cancer Center Research Institute | Identification and characterization of p53 target genes |
| Applied | Mineo Kurokawa | Department of Hematology and Oncology Graduate School of Medicine, University of Tokyo | Molecular pathogenesis and therapeutic targets of hematologcal malignancies | |
| 2010 | Basic | Seishi Ogawa | Cancer Genomics Project, Graduate School of Medicine University of Tokyo |
Identification of molecular targets in cancers through comprehensive cancer genome analysis |
| Applied | Shin Maeda | Department of Gastroenterology, Yokohama City University | Analysis of NF-kB/IKK signaling pathways in liver carcinogenesis | |
| 2009 | Basic | Toshikazu Ushijima | Carcinogenesis Division National Cancer Center Research Institute |
Establishment of a novel concept "epigenetic field for cancerization", its mechanistic clarification, and clinical application |
| 2008 | Basic | Hidenori Ichijo |
Laboratory of Cell Signaling Graduate School of Pharmaceutical Sciences The University of Tokyo |
Stress Signaling and Cancer |
| Applied | Hiroyuki Mano |
Division of Functional Genomics Jichi Medical University |
Discovery of a novel fusion-type oncogene EML4-ALK in lung cancer | |
| 2007 | Basic | Keiichi Nakayama | Department of Molecular and Cellular Biology Medical Institute of Bioregulation Kyushu University |
Ubiquitin ligases involved in cell-cycle control and cancer |
| Applied | Minoru Toyota |
First Department of Internal Medicine Sapporo Medical University |
DNA methylation as a new target for therapy in cancer | |
| 2006 | Basic | Masanori Hatakeyama | Division of Molecular Oncology Institute for Genetic Medicine Hokkaido University |
The role of Helicobacter pylori CagA in gastric carcinogenesis |
| Clinical | Johji Inazawa |
Department of Molecular Cytogenetics, Medical research institute Tokyo Medical & Dental University |
Exploring cancer-associated genes by molecular cytogenetic approach | |
| 2005 | Basic | Fuyuki Ishikawa | Laboratory of Cell Cycle Regulation Dept.of Gene Mechanisms, Graduate School of Biostudies Kyoto University |
Molecular of Chromosomal Evolution in Cancer Cells |
| Clinical | Tetsuya Mitsudomi | Department of Thoroacic Surgery Aichi Cancer Center Hospital |
Molecular pathogenesis of? lung cancer and its clinical application |